<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04471376</url>
  </required_header>
  <id_info>
    <org_study_id>WJP20200708</org_study_id>
    <nct_id>NCT04471376</nct_id>
  </id_info>
  <brief_title>The Effect of Sugammadex During Transcranial Electrical Motor Evoked Potential Monitoring in Spinal Surgery</brief_title>
  <official_title>Intraoperative Reversal of Muscle Relaxants During Transcranial Electrical Motor Evoked Potential Monitoring in Patients Undergoing Spinal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial motor evoked potential (TcMEP) monitoring is conventionally performed during&#xD;
      neurosurgical procedures without or with minimal neuromuscular blockade (NMB) because of its&#xD;
      potential interference with signal interpretation. However, full blockade offers increased&#xD;
      anesthetic management options and facilitates surgery. Here, investigators want to assess the&#xD;
      effect of Sugammadex during TcMEP in adult patients. Sugammadex is designed to encapsulate&#xD;
      rocuronium and reverse rocuronium-induced neuromuscular blockade. 64 patients undergoing&#xD;
      thoracic or lumbar spinal surgery will be randomly allocated into sugammadex group or control&#xD;
      group under a ratio of 1 to 1. Patients will receive either continuous infusion of rocuronium&#xD;
      to produce blockade maintained at least two twitches in Train-of-Four (TOF), rocuronium&#xD;
      infusion will be discontinued and 2 mg/kg of sugammadex will be infused while dura opening in&#xD;
      sugammadex group. Whereas no muscle relaxant will be given after anesthetic induction in&#xD;
      control group. The primary aim of this study is to compare mean value of amplitudes of TcMEPs&#xD;
      in abductor pollicis brevis muscles of both upper extremities 5 minutes after dura opening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The amplitude of MEP</measure>
    <time_frame>5 minutes after dura opening</time_frame>
    <description>mean value of amplitudes of TceMEPs in abductor pollicis brevis muscles of both upper extremities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amplitude of MEP</measure>
    <time_frame>10, 20, 30 and 60 minutes after dura opening</time_frame>
    <description>Mean value of amplitudes of TceMEPs in abductor pollicis brevis muscles of both upper extremities 10, 20, 30 and 60 minutes after dura opening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The latencies of MEPs</measure>
    <time_frame>5, 10, 20, 30 and 60 minutes after dura opening.</time_frame>
    <description>Mean value of latencies of TceMEPs in abductor pollicis brevis muscles of both upper extremities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>during the surgery</time_frame>
    <description>Peak respiratory pressures and incidence of peak insufflation pressure of more than 25cmH2O.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of sugammadex</measure>
    <time_frame>during and 24 hours after the surgery</time_frame>
    <description>Anaphylaxis, arrhythmias, post-procedure pain, nausea and vomiting, fever and diarrhea, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of body movement</measure>
    <time_frame>during the surgery</time_frame>
    <description>either nociception-induced movement (defined as &quot;coughing&quot; or reflexive limb movement temporally related to MEP stimulation) or excessive field movement (defined as grossly visible movement as determined by surgical and anesthesia teams).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of neuromuscular blockade</measure>
    <time_frame>At the end of surgery</time_frame>
    <description>Recurrence of neuromuscular blockade at the end of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor function assessment</measure>
    <time_frame>5 days after surgery</time_frame>
    <description>SMP-a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bleeding volume</measure>
    <time_frame>during the surgery</time_frame>
    <description>Total bleeding volume during the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Sugammadex</condition>
  <arm_group>
    <arm_group_label>Sugammadex group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP</description>
    <arm_group_label>Sugammadex group</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years&#xD;
&#xD;
          -  ASA status I-II&#xD;
&#xD;
          -  Patients undergo thoracic or lumbar spinal surgery&#xD;
&#xD;
          -  tcMEP monitoring during the surgery&#xD;
&#xD;
          -  Informed consent signed by patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥35 Kg/m-2&#xD;
&#xD;
          -  history of epilepsy or use of antiepileptic drugs, neuromuscular disorder(s)&#xD;
&#xD;
          -  history or family history of malignant hyperthermia&#xD;
&#xD;
          -  allergies to sugammadex, NMBs or other medication(s) used during general anesthesia&#xD;
&#xD;
          -  anemia, hemoglobin &lt;110g/L,&#xD;
&#xD;
          -  TcMEPs stimulate or record site infection&#xD;
&#xD;
          -  preoperative neurological dysfunction in both upper extremities&#xD;
&#xD;
          -  cardiac pacemaker&#xD;
&#xD;
          -  pregnancy and breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol, statistical analysis plan and informed consent form will be shared beginning 3 months and ending 5 years following 5 years article publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following 5 years article publication</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to ruquan.han@ccmu.edu.cn. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

